386 related articles for article (PubMed ID: 25846661)
1. Ticagrelor increases endothelial progenitor cell level compared to clopidogrel in acute coronary syndromes: A prospective randomized study.
Bonello L; Frere C; Cointe S; Laine M; Mancini J; Thuny F; Kerbaul F; Lemesle G; Paganelli F; Guieu R; Arnaud L; Dignat-George F; Sabatier F
Int J Cardiol; 2015; 187():502-7. PubMed ID: 25846661
[TBL] [Abstract][Full Text] [Related]
2. Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non-ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting: A Prospective, Randomized, Crossover Trial.
Jeong HS; Hong SJ; Cho SA; Kim JH; Cho JY; Lee SH; Joo HJ; Park JH; Yu CW; Lim DS
JACC Cardiovasc Interv; 2017 Aug; 10(16):1646-1658. PubMed ID: 28838475
[TBL] [Abstract][Full Text] [Related]
3. Platelet reactivity in patients receiving a maintenance dose of P2Y12-ADP receptor antagonists undergoing elective percutaneous coronary intervention.
Bonello L; Laine M; Thuny F; Paganelli F; Lemesle G; Roch A; Kerbaul F; Dignat-George F; Berbis J; Frere C
Int J Cardiol; 2016 Aug; 216():190-3. PubMed ID: 27179310
[TBL] [Abstract][Full Text] [Related]
4. Effects of Ticagrelor Versus Clopidogrel in Troponin-Negative Patients With Low-Risk ACS Undergoing Ad Hoc PCI.
Angiolillo DJ; Franchi F; Waksman R; Sweeny JM; Raveendran G; Teng R; Zhao Y; Carlson G; Khan N; Mehran R
J Am Coll Cardiol; 2016 Feb; 67(6):603-613. PubMed ID: 26868683
[TBL] [Abstract][Full Text] [Related]
5. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome.
Bonello L; Laine M; Kipson N; Mancini J; Helal O; Fromonot J; Gariboldi V; Condo J; Thuny F; Frere C; Camoin-Jau L; Paganelli F; Dignat-George F; Guieu R
J Am Coll Cardiol; 2014 Mar; 63(9):872-7. PubMed ID: 24291273
[TBL] [Abstract][Full Text] [Related]
6. Assessment of P2Y12 inhibitor usage and switching in acute coronary syndrome patients undergoing percutaneous coronary revascularization.
Kudaravalli M; Althouse AD; Marroquin OC; Khandhar SJ; Sharbaugh MS; Toma C; Conrad Smith AJ; Schindler JT; Lee JS; Mulukutla SR
Int J Cardiol; 2016 Nov; 223():854-859. PubMed ID: 27592042
[TBL] [Abstract][Full Text] [Related]
7. Contemporary antiplatelet therapy in acute coronary syndromes: are there differences in outcomes and discontinuation between clopidogrel and ticagrelor?
Harding SA; Holley A; Wilkins B; Fairley S; Simmonds M; Larsen PD
Intern Med J; 2017 Nov; 47(11):1298-1305. PubMed ID: 28857445
[TBL] [Abstract][Full Text] [Related]
8. Platelet-related biomarkers and their response to inhibition with aspirin and p2y
Lowenstern A; Storey RF; Neely M; Sun JL; Angiolillo DJ; Cannon CP; Himmelmann A; Huber K; James SK; Katus HA; Morais J; Siegbahn A; Steg PG; Wallentin L; Becker RC;
J Thromb Thrombolysis; 2017 Aug; 44(2):145-153. PubMed ID: 28608165
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial.
Husted S; James SK; Bach RG; Becker RC; Budaj A; Heras M; Himmelmann A; Horrow J; Katus HA; Lassila R; Morais J; Nicolau JC; Steg PG; Storey RF; Wojdyla D; Wallentin L;
Eur Heart J; 2014 Jun; 35(23):1541-50. PubMed ID: 24682844
[TBL] [Abstract][Full Text] [Related]
10. Platelet reactivity evaluated with the VASP assay following ticagrelor loading dose in acute coronary syndrome patients undergoing percutaneous coronary intervention.
Laine M; Toesca R; Berbis J; Frere C; Barnay P; Pansieri M; Peyre JP; Michelet P; Bessereau J; Camilleri E; Helaf O; Camaleonte M; Paganelli F; Dignat-George F; Bonello L
Thromb Res; 2013 Jul; 132(1):e15-8. PubMed ID: 23726090
[TBL] [Abstract][Full Text] [Related]
11. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis.
Steg PG; James S; Harrington RA; Ardissino D; Becker RC; Cannon CP; Emanuelsson H; Finkelstein A; Husted S; Katus H; Kilhamn J; Olofsson S; Storey RF; Weaver WD; Wallentin L;
Circulation; 2010 Nov; 122(21):2131-41. PubMed ID: 21060072
[TBL] [Abstract][Full Text] [Related]
12. Circulating progenitor cells and their interaction with platelets in patients with an acute coronary syndrome.
Tatsidou PT; Chantzichristos VG; Tsoumani ME; Sidiropoulou S; Ntalas IV; Goudevenos JA; Stellos K; Tselepis AD
Platelets; 2019; 30(3):314-321. PubMed ID: 29451832
[TBL] [Abstract][Full Text] [Related]
13. Switching patients from clopidogrel to novel P2Y12 receptor inhibitors in acute coronary syndrome: comparative effects of prasugrel and ticagrelor on platelet reactivity.
Lhermusier T; Voisin S; Murat G; Mejean S; Garcia C; Bataille V; Lipinski MJ; Carrié D; Sié P
Int J Cardiol; 2014 Jul; 174(3):874-6. PubMed ID: 24820749
[No Abstract] [Full Text] [Related]
14. Implementation of contemporary oral antiplatelet treatment guidelines in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a report from the GReek AntiPlatelet rEgistry (GRAPE).
Alexopoulos D; Goudevenos JA; Xanthopoulou I; Deftereos S; Sitafidis G; Kanakakis I; Hamilos M; Parissis H; Ntalas IV; Angelidis C; Petousis S; Vavuranakis M; Hahalis G; Stefanadis C;
Int J Cardiol; 2013 Oct; 168(6):5329-35. PubMed ID: 23978364
[TBL] [Abstract][Full Text] [Related]
15. Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.
Wallentin L; Lindholm D; Siegbahn A; Wernroth L; Becker RC; Cannon CP; Cornel JH; Himmelmann A; Giannitsis E; Harrington RA; Held C; Husted S; Katus HA; Mahaffey KW; Steg PG; Storey RF; James SK;
Circulation; 2014 Jan; 129(3):293-303. PubMed ID: 24170388
[TBL] [Abstract][Full Text] [Related]
16. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study.
Alexopoulos D; Galati A; Xanthopoulou I; Mavronasiou E; Kassimis G; Theodoropoulos KC; Makris G; Damelou A; Tsigkas G; Hahalis G; Davlouros P
J Am Coll Cardiol; 2012 Jul; 60(3):193-9. PubMed ID: 22789884
[TBL] [Abstract][Full Text] [Related]
17. Evaluating the risk-benefit profile of the direct-acting P2Y(12) inhibitor ticagrelor in acute coronary syndromes.
Husted S
Postgrad Med; 2011 Nov; 123(6):79-90. PubMed ID: 22104457
[TBL] [Abstract][Full Text] [Related]
18. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
[TBL] [Abstract][Full Text] [Related]
19. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S; Akerblom A; Cannon CP; Emanuelsson H; Husted S; Katus H; Skene A; Steg PG; Storey RF; Harrington R; Becker R; Wallentin L
Am Heart J; 2009 Apr; 157(4):599-605. PubMed ID: 19332184
[TBL] [Abstract][Full Text] [Related]
20. Ticagrelor: oral reversible P2Y(12) receptor antagonist for the management of acute coronary syndromes.
Cheng JW
Clin Ther; 2012 Jun; 34(6):1209-20. PubMed ID: 22521881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
